Original Article
Modern Pathology (2004) 17, 62–74, advance online publication, 19 November 2003; doi:10.1038/modpathol.3800016
Phenotypic differences between esophageal and gastric intestinal metaplasia
M Blanca Piazuelo1, Salima Haque2, Alberto Delgado1, Joanna X Du1, Fred Rodriguez1,3 and Pelayo Correa1
- 1Department of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA
- 2Department of Pathology, Tulane University Medical Center, New Orleans, LA, USA
- 3Veterans Affairs Medical Center, New Orleans, LA, USA
Correspondence: P Correa, Department of Pathology, Louisiana State University Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112, USA. E-mail: correa@lsuhsc.edu
Received 12 May 2003; Revised 16 July 2003; Accepted 1 August 2003; Published online 19 November 2003.
Abstract
Intestinal metaplasia is a cancer precursor in the esophagus and the stomach. Marked differences exist between the carcinogenic processes in the two locations in terms of natural history and clinical significance. We investigated biopsies from 52 patients with Barrett's esophagus and from 50 patients with gastric intestinal metaplasia in an attempt to throw light on their pathogenic processes. Morphologic characteristics, presence of Helicobacter pylori (H. pylori), and markers of differentiation, inflammation, and proliferation were evaluated by histochemical and immunohistochemical techniques. The area covered by incomplete type of intestinal metaplasia and the proportion of sulfomucins were significantly higher in the esophagus than in the stomach. Immunoreactivity with MUC1, MUC2, MUC5AC, Das-1, cytokeratins 7 and 20, inducible nitric oxide synthase and cyclooxygenase-2 antibodies was also significantly greater in Barrett's esophagus than in gastric intestinal metaplasia. In gastric intestinal metaplasia, the presence of MUC1, MUC5AC, Das-1 and cytokeratin 7 was restricted to areas with the incomplete type of metaplasia. Cell proliferation (Ki-67) was significantly higher in Barrett's esophagus than in gastric intestinal metaplasia. H. pylori was absent in all of the patients with Barrett's esophagus, while it was present in 70% of the patients with gastric intestinal metaplasia. Our observations made clear that Barrett's esophagus shares some phenotypic characteristics with gastric intestinal metaplasia, leading us to suggest that both could arise in response to injuries with eventual carcinogenic potential. However, the progression to more advanced lesions could be modulated by the nature of the carcinogenic insult.
Keywords:
Barrett's esophagus, gastric intestinal metaplasia, mucins, cytokeratins, Das-1, inducible nitric oxide synthase, cyclooxygenase-2, Ki-67
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Retinoid signalling in the development of the central nervous system
Nature Reviews Neuroscience Review (01 Nov 2002)
Barrett esophagus: histology and pathology for the clinician
Nature Reviews Gastroenterology & Hepatology Review (01 Aug 2009)
RESEARCH
Laboratory Investigation Research Article
Intestinal metaplasia at the gastroesophageal junction: Barrett?s, bacteria, and biomarkers
American Journal of Gastroenterology Correspondence
Modern Pathology Original Article

